208 related articles for article (PubMed ID: 11055467)
1. Results of the STOP-Hypertension-2 trial.
Hansson L
Blood Press Suppl; 2000; 2():17-20. PubMed ID: 11055467
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
3. The outcome of STOP-Hypertension-2 in relation to the 1999 WHO/ISH hypertension guidelines.
Lindholm LH
Blood Press Suppl; 2000; 2():21-4. PubMed ID: 11055468
[TBL] [Abstract][Full Text] [Related]
4. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
5. Results of the STOP-Hypertension-2 Trial.
Hansson L
Blood Press; 2000; 9(sup2):17-20. PubMed ID: 28425790
[TBL] [Abstract][Full Text] [Related]
6. [Are newer antihypertensive agents better than the older ones? Results of trials (CAPPP, STOP-2, NORDIL, INSIGHT and ALLHAT) with newer antihypertensive agents].
Hildebrandt PR; Tuxen CD; Kjeldsen SE; Lund-Johansen P; Hansson L
Ugeskr Laeger; 2001 Dec; 164(1):18-21. PubMed ID: 11810791
[TBL] [Abstract][Full Text] [Related]
7. Current recommendations for the treatment of hypertension: are they still valid?
Moser M
J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
[TBL] [Abstract][Full Text] [Related]
8. [Influence of risk factors and pharmacological treatment on mortality in patients with essential hypertension].
Román O; Cuevas G; Bunout D
Rev Med Chil; 1998 Jul; 126(7):745-52. PubMed ID: 9830766
[TBL] [Abstract][Full Text] [Related]
9. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
10. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of antihypertensive therapy.
Grossman E; Messerli FH
Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
Jamerson KA; Bakris GL; Wun CC; Dahlöf B; Lefkowitz M; Manfreda S; Pitt B; Velazquez EJ; Weber MA
Am J Hypertens; 2004 Sep; 17(9):793-801. PubMed ID: 15363822
[TBL] [Abstract][Full Text] [Related]
14. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
15. RAS inhibition in hypertension.
Ibrahim MM
J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
[TBL] [Abstract][Full Text] [Related]
16. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
17. [Treating hypertension is more important than the choice of agent; results from the largest clinical trial until now].
de Leeuw PW; Birkenhäger WH
Ned Tijdschr Geneeskd; 2003 Apr; 147(15):685-9. PubMed ID: 12722529
[TBL] [Abstract][Full Text] [Related]
18. First-line therapy for hypertension: different patients, different needs.
Massie BM
Geriatrics; 1994 Apr; 49(4):22-30. PubMed ID: 7909305
[TBL] [Abstract][Full Text] [Related]
19. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS).
JATOS Study Group
Hypertens Res; 2008 Dec; 31(12):2115-27. PubMed ID: 19139601
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hypertension in the elderly with special reference to urapidil.
Hansson L
Blood Press Suppl; 1994; 4():45-8. PubMed ID: 7804512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
